Nuvectis reports Q2 net loss of $6.3M; NXP900 Phase 1a complete; cash ~$39M proforma

Nuvectis Pharma, Inc.

2025-Q2 EPS reported -$0.56

Net loss of $6.3M for Q2 2025 vs $4.4M for Q2 2024; increase driven by NXP900 DDI study and stock-based compensation.
Cash and equivalents $26.8M at June 30; after July ATM from healthcare investor, proforma ~$39M; expected to fund into 2H 2027.
NXP900 becomes lead candidate; Phase 1a dose escalation and DDI study completed; Phase 1b program initiation imminent.
NXP800 exploring opportunities in endometrial and prostate cancer; updates expected in coming months.
R&D expenses $3.6M (incl. $1.8M stock-based comp); G&A $3.0M (incl. $1.8M stock-based comp) for Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.